Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
GSK today announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof.
-
GSK announce...
GSK announce...
-
Infants may now be protected against Meningitis B with fewer doses, adding flexibility to vaccination schedules
Healthcare professionals now have more options to help protect infants from invasive meningococcal disease (IMD) caused by serogroup B
-
ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
GEMINI 1&2 studies meet primary endpoint, demonstrating similar efficacy of two-drug regimen compared to standard three-drug regimen
-
GSK presents new results showing low rates of organ damage with long term use of Benlysta
Results showing low rates of organ damage progression in patients with active systemic lupus erythematosus treated with Benlysta
-
GSK announces changes to Vaccines and Global Manufacturing & Supply leadership
Luc Debruyne, President, Vaccines, is to leave GSK at the end of the year.
-
GSK completes Consumer Healthcare buyout
GSK has completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion*).
-
GSK submits regulatory application in Japan for once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD
GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of a regulatory application to the Japanese Ministry of Health,
-
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
Juluca maintains viral suppression with two drugs in the smallest single pill regimen
-
GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma
GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta
-
Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control
New study showed one third of patients had no exacerbations on long-term treatment with Nucala.
-
GSK’s industry-leading respiratory research and scientific innovation showcased at ATS conference
GlaxoSmithKline plc (GSK) will present at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018.
-
Simon Dingemans, Chief Financial Officer, to retire from GSK
Simon Dingemans, Chief Financial Officer, GSK, has informed the Board of his intention to retire from the Company in May 2019.
-
GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER
Total EPS 11.2p, -48% AER, -33% CER; Adjusted EPS 24.6p, -2% AER, +11% CER
-
Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD
Expanded indication approved for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’)
-
Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD
Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints
-
GSK appoints Kevin Sin as new SVP and Head of Worldwide Business Development for R&D
Kevin Sin appointed as Senior Vice President and Head of Worldwide Business Development for Pharmaceuticals Research & Development.
-
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases.
-
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
-
ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe
ViiV Healthcare announced that the European Committee for Medicinal Products for Human Use issued a Positive Opinion for Juluca.
